Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference
June 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
May 04, 2022 16:05 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 02, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
April 26, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
March 14, 2022 07:30 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial...
Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA® (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium complex
March 08, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. announced today the publication of data from an investigator-initiated study evaluating the activity of NUZYRA®...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
March 02, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...